NASDAQ:STAA - STAAR Surgical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$24.02 -0.27 (-1.11 %)
(As of 05/24/2019 04:55 AM ET)
Previous Close$24.29
Today's Range$23.95 - $24.96
52-Week Range$21.70 - $54.00
Volume417,313 shs
Average Volume437,942 shs
Market Capitalization$1.07 billion
P/E Ratio85.79
Dividend YieldN/A
Beta2.02
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers intraocular lenses (IOLs), including collamer material and silicone foldable IOLs, and nanoFLEX IOL that produces a clearer image, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in China, Korea, India, and internationally. STAAR Surgical Company was founded in 1982 and is based in Monrovia, California.

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:STAA
CUSIP85231230
Phone626-303-7902

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$123.95 million
Cash Flow$0.3304 per share
Book Value$3.09 per share

Profitability

Net Income$4.97 million

Miscellaneous

Employees475
Market Cap$1.07 billion
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) posted its quarterly earnings data on Wednesday, May, 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.06. The medical instruments supplier had revenue of $32.58 million for the quarter, compared to the consensus estimate of $32.40 million. STAAR Surgical had a return on equity of 13.22% and a net margin of 4.44%. During the same quarter in the previous year, the company earned $0.01 EPS. View STAAR Surgical's Earnings History.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for STAAR Surgical.

What price target have analysts set for STAA?

2 equities research analysts have issued twelve-month price objectives for STAAR Surgical's stock. Their forecasts range from $38.00 to $54.00. On average, they expect STAAR Surgical's share price to reach $46.00 in the next year. This suggests a possible upside of 91.5% from the stock's current price. View Analyst Price Targets for STAAR Surgical.

What is the consensus analysts' recommendation for STAAR Surgical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.

What are Wall Street analysts saying about STAAR Surgical stock?

Here are some recent quotes from research analysts about STAAR Surgical stock:
  • 1. According to Zacks Investment Research, "Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. " (5/7/2019)
  • 2. Canaccord Genuity analysts commented, "We view the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the US market now fully accessible to STAA. While the near term now looks even brighter, we think the firm’s longer-term potential, both with presbyopia (a ~1.5M-patient annual TAM by company estimates) and with full entry into the US market (the second-largest refractive market in the world) acting as major growth drivers – drivers we expect to support sustained, double- digit organic growth into the next decade and beyond. We reiterate our BUY rating and increase our price target to $32 (9.1x EV/sales on 2020E)." (6/20/2018)

Has STAAR Surgical been receiving favorable news coverage?

News articles about STAA stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. STAAR Surgical earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of STAAR Surgical's key competitors?

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include NVIDIA (NVDA), TransEnterix (TRXC), Ligand Pharmaceuticals (LGND), QUALCOMM (QCOM), Rockwell Medical (RMTI), Sorrento Therapeutics (SRNE), Tetraphase Pharmaceuticals (TTPH), Walt Disney (DIS), Broadcom (AVGO) and Karyopharm Therapeutics (KPTI).

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the folowing people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 65)
  • Ms. Deborah J. Andrews, Chief Financial Officer (Age 62)
  • Dr. Keith Holliday, Chief Technology Officer (Age 56)
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 57)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations, Direct Markets- Europe & China (Age 54)

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.66%), Baillie Gifford & Co. (4.01%), Renaissance Technologies LLC (1.68%), Northern Trust Corp (1.20%), Defender Capital LLC. (1.19%) and Goldman Sachs Group Inc. (1.02%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Institutional Ownership Trends for STAAR Surgical.

Which institutional investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., Acadian Asset Management LLC, SG Americas Securities LLC, First Trust Advisors LP and Parametric Portfolio Associates LLC. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Insider Buying and Selling for STAAR Surgical.

Which institutional investors are buying STAAR Surgical stock?

STAA stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Goldman Sachs Group Inc., Gilder Gagnon Howe & Co. LLC, Baillie Gifford & Co., AQR Capital Management LLC, Marshall Wace LLP, Defender Capital LLC. and Cadence Capital Management LLC. View Insider Buying and Selling for STAAR Surgical.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $24.02.

How big of a company is STAAR Surgical?

STAAR Surgical has a market capitalization of $1.07 billion and generates $123.95 million in revenue each year. The medical instruments supplier earns $4.97 million in net income (profit) each year or $0.28 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is http://www.staar.com/.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]


MarketBeat Community Rating for STAAR Surgical (NASDAQ STAA)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel